- FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
-
The present invention relates to a formamide compound, a preparation method therefor and an application thereof. The structure of the compound is shown in formula (I), and the definition of each variable in the formula is as provided in the description. The compound is capable of inhibiting the activity of ASK1 kinase. The compound of the present invention may be used in the treatment/prevention of diseases associated with ASK1 kinase, such as inflammatory diseases, metabolic diseases, autoimmune diseases, cardiovascular diseases, neurodegenerative diseases, cancers and other diseases.
- -
-
Paragraph 0196
(2021/05/14)
-
- Process Development of a Second Generation β-Amyloid-Cleaving Enzyme Inhibitor - Improving the Robustness of a Halogen-Metal Exchange Using Continuous Stirred-Tank Reactors
-
Process development for the synthesis of a second generation β-amyloid-cleaving enzyme (BACE1) inhibitor (1) is described. The lithiothiazole addition to the isoxazolene (5) under batch conditions was not scalable because of reaction gelling and anion instability. A continuous stirred-tank reactor flow process was developed and successfully executed on the 70 kg scale in multiple runs. In a head-to-head comparison between the continuous and batch processes, the former was clearly superior as it gave a higher yield (80 vs 63%) of the adduct (4) and better reaction control for handling the unstable lithiothiazole as a reaction intermediate. Subsequently, 4 underwent Pd-catalyzed amination with t-butyl carbamate, reductive cleavage of the N-O bond, thioamidine cyclization, and deprotection of the Boc group to provide hydropyranothiazine 2. The synthesis of 1 was completed by amidation with 5-(difluoromethoxy)picolinic acid and the successive deprotection of the benzamide group with either Silicycle-diamine or l-lysine.
- Li, Bryan,Barnhart, Richard W.,Dion, Amelie,Guinness, Steven,Happe, Alan,Hayward, Cheryl M.,Kohrt, Jeffrey,Makowski, Teresa,Maloney, Mark,Nelson, Jade D.,Nematalla, Asaad,McWilliams, J. Christopher,Peng, Zhihui,Raggon, Jeffrey,Sagal, John,Weisenburger, Gerald A.,Bao, Denghui,Gonzalez, Miguel,Lu, Jiangping,McLaws, Mark D.,Tao, Jian,Wu, Baolin
-
p. 1440 - 1453
(2021/06/21)
-
- AMINO HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory, and autoimmune diseases and cancers.
- -
-
Paragraph 01327
(2020/08/22)
-
- Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP
-
Histone acetyltransferase (HAT) p300 and its paralog CBP acetylate histone lysine side chains and play critical roles in regulating gene transcription. The HAT domain of p300/CBP is a potential drug target for cancer. Through compound screening and medicinal chemistry, novel inhibitors of p300/CBP HAT with their IC50 values as low as 620 nM were discovered. The most potent inhibitor is competitive against histone substrates and exhibits a high selectivity for p300/CBP. It inhibited cellular acetylation and had strong activity with EC50 of 1-3 μM against proliferation of several tumor cell lines. Gene expression profiling in estrogen receptor (ER)-positive breast cancer MCF-7 cells showed that inhibitor treatment recapitulated siRNA-mediated p300 knockdown, inhibited ER-mediated gene transcription, and suppressed expression of numerous cancer-related gene signatures. These results demonstrate that the inhibitor is not only a useful probe for biological studies of p300/CBP HAT but also a pharmacological lead for further drug development targeting cancer.
- Wu, Fangrui,Hua, Yuanda,Kaochar, Salma,Nie, Shenyou,Lin, Yi-Lun,Yao, Yuan,Wu, Jingyu,Wu, Xiaowei,Fu, Xiaoyong,Schiff, Rachel,Davis, Christel M.,Robertson, Matthew,Ehli, Erik A.,Coarfa, Cristian,Mitsiades, Nicholas,Song, Yongcheng
-
p. 4716 - 4731
(2020/05/05)
-
- Synthesis and biological evaluation of picolinamides and thiazole-2-carboxamides as mGluR5 (metabotropic glutamate receptor 5) antagonists
-
We described here the synthesis and biological evaluation of picolinamides and thiazole-2-carboxamides as potential mGluR5 antagonists. We found that a series of thiazole derivatives 6 showed better inhibitory activity against mGluR5. Compounds 6bc and 6bj have been identified as potent antagonists (IC50 = 274 and 159 nM) showing excellent in vitro stability profile. Molecular docking study using the crystal structure of mGluR5 revealed that our compounds 6bc and 6bj fit the allosteric binding site of mavoglurant well.
- Vu, Hoang Nam,Kim, Ji Young,Hassan, Ahmed H.E.,Choi, Kihang,Park, Jong-Hyun,Park, Ki Duk,Lee, Jae Kyun,Pae, Ae Nim,Choo, Hyunah,Min, Sun-Joon,Cho, Yong Seo
-
supporting information
p. 140 - 144
(2015/12/18)
-
- APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
-
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ASK1), thus are thus useful in treating ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.
- -
-
Paragraph 0179; 0180
(2015/07/02)
-
- APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
-
The present invention relates to compounds of Formula (I): Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.
- -
-
Paragraph 0174
(2014/07/08)
-
- HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS
-
This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.
- -
-
Page/Page column 36
(2008/12/05)
-
- Fluorinations with sulfur tetrafluoride and HF. 2. Preparation of trifluoromethylated thiazoles and isothiazoles
-
Several new trifluoromethylated thiazoles and isothiazoles have been prepared using SF4 on precursor carboxylic acids.This chemistry demonstrates the usefulness and applicability of the sulfur tetrafluoride fluorination to the preparation of novel thiazoles and isothiazoles.
- Nickson, Thomas E.
-
p. 173 - 178
(2007/10/02)
-